Shangcong Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shangcong Han has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Yong Sun
Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266071, China
4 shared publications - Anjie Dong
Department of Polymer Science and Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
2 shared publications Chunrong Zhu
Department of Pharmacy Intravenous Admixture Service, Weifang Maternal and Child Health Hospital, Weifang, People’s Republic of China
2 shared publications- Jianhua Zhang
Key Laboratory of Systems Bioengineering of the Ministry of Education, Department of Polymer Science and Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
2 shared publications Liandong Deng
2 shared publications- Zhipeng Li
Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China
2 shared publications
Latest Publications
- 15 April 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
Testosterone-Modified Liposomes Loaded with the Zn–Polyphenol Complex for Treatment of Male Infertility
In this study, we developed an androgen-mediated, testis-targeted nanodrug delivery system with both antioxidant and anti-inflammatory functions, namely, testosterone-modified epigallocatechin gallate-zinc complex liposomes (EGCG-Zn@T-Lipo), and systematically investigated its biological mechanisms and cellular effects in the treatment of orchitis. EGCG coordinated with Zn2+ to form a stable antioxidant complex, while testosterone modification enabled specific targeting to androgen receptor (AR)-positive tissues. EGCG-Zn@T-Lipo exhibited a uniform particle size, good stability, high encapsulation efficiency, and excellent biocompatibility. In LPS/nigericin-induced inflammation models, it efficiently scavenged reactive oxygen species, inhibited NOD-like receptor protein 3 (NLRP3) inflammasome activation, and reduced inflammatory cytokines, such as IL-1β and IL-18, maintaining redox homeostasis in Sertoli and Leydig cells. In RAW264.7 macrophages, it suppressed inflammatory signaling and promoted M2 polarization through liposome fusion and EGCG-Zn2+ synergistic antioxidation. In vivo, EGCG-Zn@T-Lipo showed strong testicular targeting and therapeutic efficacy, alleviating inflammation, restoring testosterone secretion, and preserving the spermatogenic structure. These results indicate that EGCG-Zn@T-Lipo achieves precise protection against testicular inflammation through testosterone-mediated targeting, the synergistic antioxidative effect of EGCG and Zn2+, and inhibition of the NLRP3 inflammasome, providing a promising nanotherapeutic strategy for testis-related inflammatory diseases.
- 15 April 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
Testosterone-Modified Liposomes Loaded with the Zn–Polyphenol Complex for Treatment of Male Infertility
In this study, we developed an androgen-mediated, testis-targeted nanodrug delivery system with both antioxidant and anti-inflammatory functions, namely, testosterone-modified epigallocatechin gallate-zinc complex liposomes (EGCG-Zn@T-Lipo), and systematically investigated its biological mechanisms and cellular effects in the treatment of orchitis. EGCG coordinated with Zn2+ to form a stable antioxidant complex, while testosterone modification enabled specific targeting to androgen receptor (AR)-positive tissues. EGCG-Zn@T-Lipo exhibited a uniform particle size, good stability, high encapsulation efficiency, and excellent biocompatibility. In LPS/nigericin-induced inflammation models, it efficiently scavenged reactive oxygen species, inhibited NOD-like receptor protein 3 (NLRP3) inflammasome activation, and reduced inflammatory cytokines, such as IL-1β and IL-18, maintaining redox homeostasis in Sertoli and Leydig cells. In RAW264.7 macrophages, it suppressed inflammatory signaling and promoted M2 polarization through liposome fusion and EGCG-Zn2+ synergistic antioxidation. In vivo, EGCG-Zn@T-Lipo showed strong testicular targeting and therapeutic efficacy, alleviating inflammation, restoring testosterone secretion, and preserving the spermatogenic structure. These results indicate that EGCG-Zn@T-Lipo achieves precise protection against testicular inflammation through testosterone-mediated targeting, the synergistic antioxidative effect of EGCG and Zn2+, and inhibition of the NLRP3 inflammasome, providing a promising nanotherapeutic strategy for testis-related inflammatory diseases.
- Open Access
- 1 September 2023
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 15, 957-975
Role of Human Monocarboxylate Transporter 1 (hMCT1) and 4 (hMCT4) in Tumor Cells and the Tumor Microenvironment
In recent years, the abnormal glucose metabolism of tumor cells has attracted increasing attention. Abnormal glucose metabolism is closely related to the occurrence and development of tumors. Monocarboxylate transporters (MCTs) transport the sugar metabolites lactic acid and pyruvate, which affect glucose metabolism and tumor progression in a variety of ways. Thus, research has recently focused on MCTs and their potential functions in cancer. The MCT superfamily consists of 14 members. MCT1 and MCT4 play a crucial role in the maintenance of intracellular pH in tumor cells by transporting monocarboxylic acids (such as lactate, pyruvate and butyrate). MCT1 and MCT4 are highly expressed in a variety of tumor cells and are involved the proliferation, invasion and migration of tumor cells, which are closely related to the prognosis of cancer. Because of their important functions in tumor cells, MCT1 and MCT4 have become potential targets for cancer treatment. In this review, we focus on the structure, function and regulation of MCT1 and MCT4 and discuss the developed inhibitors of MCT1 and MCT4 to provide more comprehensive information that might aid in the development of strategies targeting MCTs in cancer.
- 1 September 2023
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 15, 957-975
Open AccessRole of Human Monocarboxylate Transporter 1 (hMCT1) and 4 (hMCT4) in Tumor Cells and the Tumor Microenvironment
In recent years, the abnormal glucose metabolism of tumor cells has attracted increasing attention. Abnormal glucose metabolism is closely related to the occurrence and development of tumors. Monocarboxylate transporters (MCTs) transport the sugar metabolites lactic acid and pyruvate, which affect glucose metabolism and tumor progression in a variety of ways. Thus, research has recently focused on MCTs and their potential functions in cancer. The MCT superfamily consists of 14 members. MCT1 and MCT4 play a crucial role in the maintenance of intracellular pH in tumor cells by transporting monocarboxylic acids (such as lactate, pyruvate and butyrate). MCT1 and MCT4 are highly expressed in a variety of tumor cells and are involved the proliferation, invasion and migration of tumor cells, which are closely related to the prognosis of cancer. Because of their important functions in tumor cells, MCT1 and MCT4 have become potential targets for cancer treatment. In this review, we focus on the structure, function and regulation of MCT1 and MCT4 and discuss the developed inhibitors of MCT1 and MCT4 to provide more comprehensive information that might aid in the development of strategies targeting MCTs in cancer.
- Open Access
- 6 December 2022
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 17, 6031-6046
Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy
Introduction: Sunitinib, a first-line therapy with a certain effect, was utilized in the early stages of renal cell carcinoma treatment. However, its clinical toxicity, side effects, and its limited bioavailability, resulted in inadequate clinical therapeutic efficacy. Building neoteric, simple, and safe drug delivery systems with existing drugs offers new options. Therefore, we aimed to construct a micelle to improve the clinical efficacy of sunitinib by reusing ibuprofen. Methods: We synthesized the sialic acid-poly (ethylene glycol)-ibuprofen (SA-PEG-IBU) amphipathic conjugate in two-step reaction. The SA-PEG-IBU amphiphilic conjugates can form into stable SPI nanomicelles in aqueous solution, which can be further loaded sunitinib (SU) to obtain the SPI/SU system. Following nanomicelle creation, sialic acid exposed to the nanomicelle surface can recognize the overexpressed E-selectin receptor on the membrane of cancer cells to enhance cellular uptake. The properties of morphology, stability, and drug release about the SPI/SU nanomicelles were investigated. Confocal microscopy and flow cytometry were used to assess the cellular uptake efficiency of nanomicelles in vitro. Finally, a xenograft tumor model in nude mice was constructed to investigate the body distribution and tumor suppression of SPI/SU in vivo. Results: The result showed that SPI nanomicelles exhibited excellent tumor targeting performance and inhibited the migration and invasion of tumor cell in vitro. The SPI nanomicelles can improve the accumulation of drugs in the tumor site that showed effective tumor inhibition in vivo. In addition, H&E staining and immunohistochemical analysis demonstrated that the SPI/SU nanomicelles had a superior therapeutic effect and lower biotoxicity. Conclusion: The SPI/SU nanomicelles displayed excellent anti-tumor ability, and can suppress the metastasis of tumor cell by decreasing the expression of Cyclooxygenase-2 due to the ibuprofen, providing an optimistic clinical application potential by developing a simple but safe drug delivery system.
- 6 December 2022
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 17, 6031-6046
Open AccessCombined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy
Introduction: Sunitinib, a first-line therapy with a certain effect, was utilized in the early stages of renal cell carcinoma treatment. However, its clinical toxicity, side effects, and its limited bioavailability, resulted in inadequate clinical therapeutic efficacy. Building neoteric, simple, and safe drug delivery systems with existing drugs offers new options. Therefore, we aimed to construct a micelle to improve the clinical efficacy of sunitinib by reusing ibuprofen. Methods: We synthesized the sialic acid-poly (ethylene glycol)-ibuprofen (SA-PEG-IBU) amphipathic conjugate in two-step reaction. The SA-PEG-IBU amphiphilic conjugates can form into stable SPI nanomicelles in aqueous solution, which can be further loaded sunitinib (SU) to obtain the SPI/SU system. Following nanomicelle creation, sialic acid exposed to the nanomicelle surface can recognize the overexpressed E-selectin receptor on the membrane of cancer cells to enhance cellular uptake. The properties of morphology, stability, and drug release about the SPI/SU nanomicelles were investigated. Confocal microscopy and flow cytometry were used to assess the cellular uptake efficiency of nanomicelles in vitro. Finally, a xenograft tumor model in nude mice was constructed to investigate the body distribution and tumor suppression of SPI/SU in vivo. Results: The result showed that SPI nanomicelles exhibited excellent tumor targeting performance and inhibited the migration and invasion of tumor cell in vitro. The SPI nanomicelles can improve the accumulation of drugs in the tumor site that showed effective tumor inhibition in vivo. In addition, H&E staining and immunohistochemical analysis demonstrated that the SPI/SU nanomicelles had a superior therapeutic effect and lower biotoxicity. Conclusion: The SPI/SU nanomicelles displayed excellent anti-tumor ability, and can suppress the metastasis of tumor cell by decreasing the expression of Cyclooxygenase-2 due to the ibuprofen, providing an optimistic clinical application potential by developing a simple but safe drug delivery system.
- Open Access
- 1 December 2021
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 16, 7861-7873
Layered Double Hydroxide Modified with Deoxycholic and Hyaluronic Acids for Efficient Oral Insulin Absorption
Introduction: This study aimed to construct a layered double hydroxide (LDH) nanoparticle delivery system that was modified by deoxycholic acid (DCA) and hyaluronic acid (HA) to increase the bioavailability of oral insulin. Methods: LDH-DCA-HA was synthesized by the hybridization of DCA and HA with LDH. Subsequently, insulin was loaded onto LDH-DCA-HA, resulting in the formation of [email protected] The in vivo and in vitro mechanisms of insulin release, as well as the efficiency of insulin absorption, were analyzed before and after DCA-HA modification. Results: MTT assay showed that there was satisfactory biocompatibility between LDH-DCA-HA and Caco-2 cells at a concentration below 1000 μg/mL. Flow cytometry analysis revealed that Caco-2 cells absorbed [email protected] more readily than insulin. Measurement of transepithelial electrical resistance indicated that [email protected] induced the reversible opening of tight cell junctions, thereby facilitating its absorption. This was confirmed via laser confocal microscopy analysis, revealing that a large amount of zonula occludens-1 tight junction (TJ) protein was utilized for the paracellular pathway of nanoparticles. We also measured the blood glucose levels of type I diabetic mice and found that oral [email protected] exerted a steady hypoglycemic effect lasting 12 h, with a small range of postprandial blood glucose fluctuation. Immunofluorescence analysis showed that the strong penetration ability of [email protected] allowed insulin to enter epithelial cells more readily than free insulin. Finally, immunohistochemical analysis of anti-SLC10A1 protein confirmed that the cholic acid transporter receptor protein played a key role in the functioning of [email protected] Conclusion: LDH nanoparticles modified by DCA and HA improved the absorption efficiency of insulin by opening the TJs of cells and interacting with the cholic acid transporter receptor protein.
- 1 December 2021
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 16, 7861-7873
Open AccessLayered Double Hydroxide Modified with Deoxycholic and Hyaluronic Acids for Efficient Oral Insulin Absorption
Introduction: This study aimed to construct a layered double hydroxide (LDH) nanoparticle delivery system that was modified by deoxycholic acid (DCA) and hyaluronic acid (HA) to increase the bioavailability of oral insulin. Methods: LDH-DCA-HA was synthesized by the hybridization of DCA and HA with LDH. Subsequently, insulin was loaded onto LDH-DCA-HA, resulting in the formation of [email protected] The in vivo and in vitro mechanisms of insulin release, as well as the efficiency of insulin absorption, were analyzed before and after DCA-HA modification. Results: MTT assay showed that there was satisfactory biocompatibility between LDH-DCA-HA and Caco-2 cells at a concentration below 1000 μg/mL. Flow cytometry analysis revealed that Caco-2 cells absorbed [email protected] more readily than insulin. Measurement of transepithelial electrical resistance indicated that [email protected] induced the reversible opening of tight cell junctions, thereby facilitating its absorption. This was confirmed via laser confocal microscopy analysis, revealing that a large amount of zonula occludens-1 tight junction (TJ) protein was utilized for the paracellular pathway of nanoparticles. We also measured the blood glucose levels of type I diabetic mice and found that oral [email protected] exerted a steady hypoglycemic effect lasting 12 h, with a small range of postprandial blood glucose fluctuation. Immunofluorescence analysis showed that the strong penetration ability of [email protected] allowed insulin to enter epithelial cells more readily than free insulin. Finally, immunohistochemical analysis of anti-SLC10A1 protein confirmed that the cholic acid transporter receptor protein played a key role in the functioning of [email protected] Conclusion: LDH nanoparticles modified by DCA and HA improved the absorption efficiency of insulin by opening the TJs of cells and interacting with the cholic acid transporter receptor protein.
- 1 July 2021
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 203, 111733
Reduction-sensitive polymeric micelles as amplifying oxidative stress vehicles for enhanced antitumor therapy
- 1 July 2021
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 203, 111733
Reduction-sensitive polymeric micelles as amplifying oxidative stress vehicles for enhanced antitumor therapy
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Drug Delivery
- Vol. 28 (1) , 2329-2347
Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors
In recent years, the incidence of various types of tumors has gradually increased, and it has also been found that there is a certain correlation between abnormal glucose and lipid metabolism and tumors. Glycolipid metabolism can promote tumor progression through multiple pathways, and the expression of related genes also directly or indirectly affects tumor metabolism, metastasis, invasion, and apoptosis. There has been much research on targeted drug delivery systems designed for abnormal glucose and lipid metabolism due to their accuracy and efficiency when used for tumor therapy. In addition, gene mutations have become an important factor in tumorigenesis. For this reason, gene therapy consisting of drugs designed for certain specifically expressed genes have been transfected into target cells to express or silence the corresponding proteins. Targeted gene drug vectors that achieve their corresponding therapeutic purposes are also rapidly developing. The genes related to glucose and lipid metabolism are considered as the target, and a corresponding gene drug carrier is constructed to influence and interfere with the expression of related genes, so as to block the tumorigenesis process and inhibit tumor growth. Designing drugs that target genes related to glucose and lipid metabolism within tumors is considered to be a promising strategy for the treatment of tumor diseases. This article summarizes the chemical drugs/gene drug delivery systems and the corresponding methods used in recent years for the treatment of abnormal glucose and lipid metabolism of tumors, and provides a theoretical basis for the development of glucolipid metabolism related therapeutic methods. Graphical Abstract
- 1 January 2021
- Published by Taylor & Francis in Drug Delivery
- Vol. 28 (1) , 2329-2347
Open AccessResearch progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors
In recent years, the incidence of various types of tumors has gradually increased, and it has also been found that there is a certain correlation between abnormal glucose and lipid metabolism and tumors. Glycolipid metabolism can promote tumor progression through multiple pathways, and the expression of related genes also directly or indirectly affects tumor metabolism, metastasis, invasion, and apoptosis. There has been much research on targeted drug delivery systems designed for abnormal glucose and lipid metabolism due to their accuracy and efficiency when used for tumor therapy. In addition, gene mutations have become an important factor in tumorigenesis. For this reason, gene therapy consisting of drugs designed for certain specifically expressed genes have been transfected into target cells to express or silence the corresponding proteins. Targeted gene drug vectors that achieve their corresponding therapeutic purposes are also rapidly developing. The genes related to glucose and lipid metabolism are considered as the target, and a corresponding gene drug carrier is constructed to influence and interfere with the expression of related genes, so as to block the tumorigenesis process and inhibit tumor growth. Designing drugs that target genes related to glucose and lipid metabolism within tumors is considered to be a promising strategy for the treatment of tumor diseases. This article summarizes the chemical drugs/gene drug delivery systems and the corresponding methods used in recent years for the treatment of abnormal glucose and lipid metabolism of tumors, and provides a theoretical basis for the development of glucolipid metabolism related therapeutic methods. Graphical Abstract
- 1 February 2019
- Published by Elsevier in Progress in Organic Coatings
- Vol. 127, 211-221
Novel dual-functional coating with underwater self-healing and anti-protein-fouling properties by combining two kinds of microcapsules and a zwitterionic copolymer
- 1 February 2019
- Published by Elsevier in Progress in Organic Coatings
- Vol. 127, 211-221
Novel dual-functional coating with underwater self-healing and anti-protein-fouling properties by combining two kinds of microcapsules and a zwitterionic copolymer
- 8 June 2016
- Published by Springer Nature in Transactions of Tianjin University
- Vol. 22 (3) , 237-246
Layered double hydroxide modified by PEGylated hyaluronic acid as a hybrid nanocarrier for targeted drug delivery
- 8 June 2016
- Published by Springer Nature in Transactions of Tianjin University
- Vol. 22 (3) , 237-246
Layered double hydroxide modified by PEGylated hyaluronic acid as a hybrid nanocarrier for targeted drug delivery
- 1 February 2014
- Published by Elsevier in Acta Biomaterialia
- Vol. 10 (2) , 670-679
Contribution of hydrophobic/hydrophilic modification on cationic chains of poly(ε-caprolactone)-graft-poly(dimethylamino ethylmethacrylate) amphiphilic co-polymer in gene delivery
- 1 February 2014
- Published by Elsevier in Acta Biomaterialia
- Vol. 10 (2) , 670-679
Contribution of hydrophobic/hydrophilic modification on cationic chains of poly(ε-caprolactone)-graft-poly(dimethylamino ethylmethacrylate) amphiphilic co-polymer in gene delivery